Analysts Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $326.25

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average rating of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $326.25.

KRYS has been the topic of a number of research reports. Jefferies Financial Group boosted their price objective on Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research report on Tuesday, February 17th. Guggenheim increased their target price on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Wolfe Research initiated coverage on Krystal Biotech in a research note on Friday. They set a “peer perform” rating on the stock. Weiss Ratings cut Krystal Biotech from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday. Finally, Citigroup upped their price objective on Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS opened at $245.39 on Friday. Krystal Biotech has a one year low of $122.80 and a one year high of $298.30. The company has a market cap of $7.17 billion, a price-to-earnings ratio of 35.82 and a beta of 0.49. The firm has a 50 day simple moving average of $267.34 and a 200 day simple moving average of $230.46.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The firm had revenue of $107.11 million for the quarter, compared to analysts’ expectations of $105.30 million. As a group, analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $263.21, for a total value of $6,580,250.00. Following the completion of the transaction, the insider directly owned 1,403,155 shares in the company, valued at approximately $369,324,427.55. This represents a 1.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dino A. Rossi sold 18,950 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $261.41, for a total transaction of $4,953,719.50. Following the transaction, the director directly owned 78,691 shares of the company’s stock, valued at $20,570,614.31. The trade was a 19.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 129,164 shares of company stock valued at $34,538,578. 13.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. UMB Bank n.a. increased its position in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the period. Optimize Financial Inc boosted its position in Krystal Biotech by 1.4% during the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after acquiring an additional 40 shares during the last quarter. Perigon Wealth Management LLC grew its holdings in Krystal Biotech by 0.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after acquiring an additional 41 shares during the period. Regal Investment Advisors LLC grew its holdings in Krystal Biotech by 1.0% during the 4th quarter. Regal Investment Advisors LLC now owns 4,360 shares of the company’s stock worth $1,075,000 after acquiring an additional 44 shares during the period. Finally, Crossmark Global Holdings Inc. raised its position in shares of Krystal Biotech by 2.7% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company’s stock worth $524,000 after acquiring an additional 55 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.